$61.33 -0.8 -1.2%
Last Trade - 26/02/21
| Market Cap | £99.48bn |
| Enterprise Value | £124.53bn |
| Revenue | £30.52bn |
| Position in Universe | 83rd / 6715 |
| Industry | Market | |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
| Year End 31st Dec | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021E | 2022E | CAGR / Avg | |
|---|---|---|---|---|---|---|---|---|---|---|
| 16,560 | 19,427 | 20,776 | 22,561 | 26,145 | 42,518 | 46,328 | 48,311 | +20.8% | ||
| -22.3 | +117.6 | +27.1 | +24.5 | -37.4 | -87.1 | +2,345 | +7.57 | |||
|
x
|
||||||||||
| Profitability | ||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
| Cashflow | ||||||||||
| Dividends | ||||||||||
| Balance Sheet | ||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing % | |||
| Net Gearing % | |||
| Cash / Assets % |
| Liquidity (ttm) | ||
|---|---|---|
| Curr. Ratio | ||
| Quick Ratio | ||
| Interest Cov. | ||
| Efficiency (ttm) | ||
|---|---|---|
| Asset Turnover | ||
| Recs Turnover | ||
| Stock Turnover | ||
| Latest interim period vs. prior period | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
| 3yr Compound Annual Growth Rate | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
Revenue
Net Income
Normalised EPS
PE Ratio Range
Dividend Yield Range
|
Price Target:
( below Price)
|
31st Dec 2021
|
31st Dec 2022
|
||||
|---|---|---|---|---|---|---|
| Est. Long Term Growth Rate: |
Net Profit () |
EPS () |
DPS () |
Net Profit () |
EPS () |
DPS () |
| Consensus Estimate | ||||||
| 1m Change | ||||||
| 3m Change | ||||||
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company's pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics. Small molecule drugs are administered orally in the form of a pill or tablet. Biologics are administered to patients through injections or by infusion. Its products include Empliciti, Opdivo, Sprycel, Yervoy, Eliquis, Orencia, Baraclude, Hepatitis C Franchise, Reyataz Franchise and Sustiva Franchise. It offers products for a range of therapeutic classes, which include virology, including human immunodeficiency virus (HIV) infection; oncology; immunoscience, and cardiovascular. Its products are sold to wholesalers, retail pharmacies, hospitals, government entities and the medical profession across the world. Its subsidiaries are Celgene Corp and MyoKardia, Inc.
| Last Annual | December 31st, 2020 |
| Last Interim | December 31st, 2020 |
| Incorporated | August 11, 1933 |
| Public Since | July 5, 1929 |
| No. of Shareholders: | 36,187 |
| No. of Employees: | 30,250 |
| Sector | Healthcare |
| Industry | Pharmaceuticals |
| Index | FTSE Global 100, S&P Composite 1500 , S&P 500 , S&P 500 Health Care (sector), |
| Exchange | New York Stock Exchange |
| Shares in Issue | 2,259,751,518 |
| Free Float | (0.0%) |
| Eligible for |
ISAs
SIPPs
|
| Address | 430 E 29th St Fl 14, NEW YORK, 10016-8367, United States |
| Web | https://www.bms.com/ |
| Phone | +1 212 5464000 |
| Contact | Tim Power (Vice President of Investor Relations) |
| Auditors | Deloitte & Touche LLP |
As of 26/02/21, shares in Bristol-Myers Squibb Co are trading at $61.33, giving the company a market capitalisation of £99.48bn. This share price information is delayed by 15 minutes.
Shares in Bristol-Myers Squibb Co are currently trading at $61.33 and the price has moved by 2.94% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Bristol-Myers Squibb Co price has moved by -20.59% over the past year.
Of the analysts with advisory recommendations for Bristol-Myers Squibb Co, there are there are currently 7 "buy" , 5 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Bristol-Myers Squibb Co is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Bristol-Myers Squibb Co is scheduled to issue upcoming financial results on the following dates:
The Bristol-Myers Squibb Co dividend yield is 2.93% based on the trailing twelve month period.
Last year, Bristol-Myers Squibb Co paid a total dividend of 1.8, and it currently has a trailing dividend yield of 2.93%. Looking ahead, Bristol-Myers Squibb Co has not announced an ex-dividend date yet.
Bristol-Myers Squibb Co has yet to annouce their ex-dividend date. The historic dividend yield on Bristol-Myers Squibb Co shares is currently 2.93%.
To buy shares in Bristol-Myers Squibb Co you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
Shares in Bristol-Myers Squibb Co are currently trading at $61.33, giving the company a market capitalisation of £99.48bn.
Here are the trading details for Bristol-Myers Squibb Co:
Based on an overall assessment of its quality, value and momentum, Bristol-Myers Squibb Co is currently classified as a Style Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Shares in Bristol-Myers Squibb Co are currently priced at $61.33. At that level they are trading at 22.5% discount to the analyst consensus target price of 0.00.
Analysts covering Bristol-Myers Squibb Co currently have a consensus Earnings Per Share (EPS) forecast of 7.48 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Bristol-Myers Squibb Co. Over the past six months, the relative strength of its shares against the market has been -10.12%. At the current price of $61.33, shares in Bristol-Myers Squibb Co are trading at 0.64% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Bristol-Myers Squibb Co PE ratio based on its reported earnings over the past 12 months is 0.200k. The shares are currently trading at $61.33.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Bristol-Myers Squibb Co's management team is headed by:
Here are the top five shareholders of Bristol-Myers Squibb Co based on the size of their shareholding:
